Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Zelenectide pevedotin - Bicycle Therapeutics

Next Previous
X
Search
Drug Profile

Zelenectide pevedotin - Bicycle Therapeutics

Alternative Names: BT 8009

Latest Information Update: 17 Mar 2025

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bicycle Therapeutics
  • Class Antineoplastics; Auristatins; Bicyclic peptide drug conjugates; Bicyclic peptides; Drug conjugates; Peptides
  • Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Breast cancer
  • Phase II/III Urogenital cancer
  • Phase I/II Solid tumours

Most Recent Events

  • 07 Mar 2025 Phase-III clinical trials in Breast cancer (Second-line therapy or greater, Inoperable/Unresectable, Late-stage disease, Metastatic disease) in USA (IV) (NCT06840483) (EUCT-2024-517868-33-00)
  • 03 Mar 2025 BicycleTx Therapeutics plans a phase II trial for Breast cancer (Late-stage disease, Recurrent, Inoperable/Unresectable, Metastatic disease, Second-line therapy or greater) in March 2025 (IV) (NCT06840483)
  • 25 Feb 2025 Efficacy and adverse events data from the phase I/II Duravelo-1 trial in solid tumours released by Bicycle Therapeutics

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top